Due to the significant impact of cardiotoxicity, researchers need to develop effective strategies for preventing, monitoring, and managing this condition. Creative Biolabs employs high-throughput screening techniques to assess the impact of potential drugs on cardiac cells, particularly by examining their electrophysiological properties and cell survival rates. To enhance the relevance of our findings, we utilize humanized animal models and cardiac cells derived from stem cells to replicate human heart responses effectively. Moreover, we have created and applied biomarker detection methods to identify early signs of cardiac injury, including cardiac-specific troponin levels.

Introduction

Cardiotoxicity is defined as the harm or impairment inflicted on the heart by specific drugs, chemotherapy treatments, or various therapeutic approaches. This can result in heart disease, heart failure, or other serious cardiovascular problems. Consequently, emphasizing the prevention and management of cardiotoxicity is essential.

Creative Biolabs provides thorough assessments of cardiotoxicity risks. By leveraging cutting-edge laboratory methods and biomarker evaluations, we can detect drug-induced cardiotoxicity at an early stage. We also utilize a range of animal models that replicate human cardiac physiological traits, allowing us to investigate the impacts of drugs on heart function across various doses and timeframes. Moreover, our efforts support the creation of novel cardioprotective agents aimed at minimizing cardiac cell injury, improving heart performance, preventing heart attacks, and alleviating ischemia-reperfusion damage.

Fig.1 Cardiotoxicity Monitoring Strategies.^1,3

Services

With the advancement of biomedical technologies, such as cardiac imaging and the detection of molecular biomarkers, the methods for monitoring and intervening in cardiac toxicity are continually evolving. Creative Biolabs provides a range of services designed to assist pharmaceutical and biotechnology companies in managing cardiotoxicity throughout different phases of drug development.

Cardioprotective Agent Development Service

In our labs, we employ molecular biology and biochemistry to identify molecular targets associated with heart disease, such as antioxidant enzymes, inflammatory factors, and ion channels. Meanwhile, we utilize genomics and proteomics to study the expression changes of genes and proteins in heart disease models. We plan to use high-throughput screening techniques to identify candidate drugs from our compound library. Through computer-aided drug design (CADD) and structural biology, we aim to optimize these candidate compounds to enhance their selectivity and effectiveness. Furthermore, we will test the bioactivity of potential cardioprotective agents in in vitro cell models, including cardiomyocytes and cardiac fibroblasts. Also, we can conduct pharmacological and toxicological evaluations using animal models, such as mice and rats.

Cardiotoxicity Biomarker Discovery Service

At Creative Biolabs, our biomarker discovery services for cardiotoxicity assist clients in identifying and validating biomarkers that can predict or signal cardiotoxic effects linked to different treatments, including chemotherapy and new drug candidates. Our services play a crucial role in improving the drug development process and ensuring compliance with regulatory requirements.

We have developed an efficient high-throughput screening platform aimed at swiftly evaluating the potential cardiotoxic effects of a wide array of compounds. Currently, our high-throughput RNA sequencing platform enables the analysis of gene expression changes in cells affected by cardiac toxicity, allowing us to identify a wide range of characteristic genes associated with this toxicity. Additionally, by employing techniques such as mass spectrometry, we can compare the protein expression profiles of healthy cells or tissues with those impacted by cardiotoxicity, aiding our clients in the search for potential protein biomarkers. In recent years, we have also been actively developing biosensors capable of real-time monitoring of cardiotoxicity markers, enhancing the sensitivity and accuracy of detections.

Fig.2 The Cardioprotective Activity Analysis of DMSA NPs.^2,3

Why Choose Us?

• Reliability and Compliance: Adhering to the standards set by international regulatory bodies, to ensure the integrity and compliance of research data.
• Comprehensive Service Offering: Delivering a full spectrum of services from preclinical research to post-marketing lifecycle management, including cardiac toxicity prediction, risk assessment, and monitoring.
• Expert Team: Featuring a specialized multidisciplinary team comprising cardiovascular disease specialists and data analysts to ensure high-quality, in-depth research.
• Agile Responsiveness: Quickly adapting to client needs and market changes, offering tailored solutions that enhance the research and development process.
• Cost-effectiveness: Reducing research and development costs through the use of advanced technologies and efficient processes, thereby accelerating time-to-market and enhancing business competitiveness.

Cardiotoxicity, recognized as a significant side effect, is gaining increasing attention. Creative Biolabs is committed to offering comprehensive services for the prevention and intervention of cardiotoxicity, assisting clients in effectively assessing and managing potential risks. Feel free to contact us anytime for more information about our services on preventing and managing cardiotoxicity.

References

1. El-Cheikh, Jean, et al. "Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies." Blood Cancer Journal 13.1 (2023): 83.
2. Xiong, Fei, et al. "Cardioprotective activity of iron oxide nanoparticles." Scientific Reports 5.1 (2015): 8579.
3. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only | Not For Clinical Use